Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats

Hypertension Research - Clinical and Experimental

Volumn 19, Issue 4, 1996, Pages 229-238

  Wegner, Max ^a   Ganten, Detlev ^b   Stasch, Johannes Peter ^a  

^a BAYER AG   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

(S) thiorphan; ANP; BNP; CNP; Ecadotril; Neutral endopeptidase 24.11; TGR(m(Ren2)27)

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; RENIN; SODIUM; THIORPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME INHIBITION; HEART FAILURE; HEMODYNAMICS; HORMONE BLOOD LEVEL; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PLASMA RENIN ACTIVITY; RAT; TRANSGENE; URINARY EXCRETION;

EID: 0030454061     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.19.229     Document Type: Article

References (56)

1. Sudoh T, Minamino N, Kangawa K, Matsuo H: C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168: 863-870.
2. Sudoh T, Minamino N, Kangawa K, Matsuo H: Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun 1988; 155: 726-732.
3. Ruskoaho H: Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992; 44: 479-602.
4. Olins GM, Spear KL, Siegel NR, Zurcher-Neely HA: Inactivation of atrial natriuretic factor by the renal brush border. Biochim Biophys Acta 1987; 901: 97-100.
5. Sonnenberg JL, Sakane Y, Jeng AY, et al: Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 1988; 9: 173-180.
6. Koehn JA, Norman JA, Jones BN, LeSueur L, Sakane Y, Ghai RD: Degradation of atrial natriuretic factor by kidney cortex membranes. Isolation and characterization of the primary proteolytic product. J Biol Chem 1987; 262: 11623-11627.
7. Erdös EG, Skidgel RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3: 145-151.
8. Saito Y, Nakao K, Itoh H, et al: Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989; 158: 360-368.
9. Itoh H, Nakao K, Kambayashi Y, et al: Occurence of a novel cardiac natriuretic peptide in rats. Biochem Biophys Res Commun 1989; 161: 732-739.
10. Morita E, Yasue H, Yoshimura M, et al: Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
11. Mukoyama M, Nakao K, Saito Y, et al: Brain natriuretic peptide (BNP) as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
12. Mukoyama M, Nakao K, Obata K, et al: Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun 1991; 180: 431-436.
13. Arimura JJ, Minamino N, Kangawa K, Matsuo H: Isolation and identification of C-type natriuretic peptide in chicken brain. Biochem Biophys Res Commun 1991; 174: 142-148.
14. Dussaule JC, Michel C, Peraldi MN, et al: Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic renal failure. Clin Sci 1993; 84: 31-39.
15. Lefrancois P, Clerc G, Duchier J, et al: Antihypertensive activity of sinorphan. Lancet 1990; 336: 307-308.
16. Kahn JC, Patey M, Dubois-Rande JL, et al: Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990; 335: 118-119.
17. Lang CC, Motwani JJ, Coutie WJR, Struthers AD: Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci 1992; 82: 619-623.
18. Hirata Y, Suzuki Y, Suzuki E, et al: Mechanisms underlying the augmented responses of desoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors. J Hypertens 1994; 12: 367-374.
19. Bachmann S, Peters J, Engler E, Ganten D, Mullins J: Transgenic rats carrying the mouse renin gene: morphological characterization of a low-renin hypertension model. Kidney Int 1992; 41:.24-36.
20. Stasch JP, Hirth-Dietrich C, Ganten D, Wegner M: Cardiorenal consequences of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens 1996; 9: 795-802.
21. Wegner M, Hirth-Dietrich C, Stasch JP: Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Cardiovasc Res 1996; 31: 891-898.
22. Jin H, Mathews C, Chen YF, et al: Effects of acute and chronic blockade of neutral endopeptidase with SCH 34826 on NaCI-sensitive hypertension in spontaneously hypertensive rats. Am J Hypertens 1992; 5: 210-218.
23. Seymour AA, Norman JA, Assad MM, et al: Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11. and clearance receptors. J Pharmacol Exp Ther 1991; 256: 1002-1009.
24. Wegner M, Stasch JP, Hirth-Dietrich C, Dressel J, Voges KP, Kazda S: Interaction of a neutral endopeptidase inhibitor with an ANP-C receptor ligand in anesthetized dogs. Clin Exp Hypertens 1995; 17: 861-876.
25. Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H: Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and hemodynamic effects. J Hypertens 1991; 9: 955-962.
26. Singer DR, Markandu ND, Buckley MG, Miller MA, Sagnella GA, MacGregor GA: Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension 1991; 18: 798-804.
27. Kosoglou T, Herren JM, Chen R, Given B, Sybertz EJ, Affrime MB: Antihypertensive effect of the atriopeptidase inhibitor SCH 34826 in essential hypertension. Circulation 1990; 82: 2201 (Abstract).
28. O'Connell JE, Jardine AG, Davidson G, Connell JMC: Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992; 10: 271-277.
29. Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T: C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3′,5′-monophosphate. Hypertension 1992; 19: 320-325.
30. Seymour AA, Asaad MM, Oboa Offei BE, Rornyak PL, Fennell S, Rogers WL: Potentiation of brain natriuretic peptide by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats. J Pharmacol Exp Ther 1992; 262: 60-70.
31. Hirata Y, Suzuki E, Hayakawa H, et al: Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J Cardiovasc Pharmacol 1994; 23: 283-290.
32. Lang CC, Motwani JG, Coutie W, Struthers AD: Influence of candoxatril on plasma brain natriuretic peptide in heart failure (Letter). Lancet 1991; ii: 255.
33. Norman JA, Little D, Bolgar M, Di Donato G: Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun 1991; 175: 22-30.
34. Hirata Y, Matsuoka H, Hayakawa H, et al: Role of endogenous atrial natriuretic peptide in regulating sodium excretion in SHR: effects of neutral endopeptidase inhibition. Hypertension 1991; 17: 1025-1032.
35. Nakao K, Mukoyama M, Hosoda K, et al: Synthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991; 69: 1500-1506.
36. Koller KJ, Lowe DG, Bennett GL, et al: Selective activation of the B-natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 1991; 252: 120-123.
37. Luk JKH, Wong EFC, Wong NLM: Absence of C-type natriuretic peptide receptors in hamster glomeruli. Nephron 1994; 67: 226-230.
38. Furuya M, Takehisa M, Minamitake Y, Kitajima Y, Hayashi Y: Novel natriuretic peptide, CNP, potently stimulates cyclic GMP production in rat cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1990; 170: 201-208.
39. Wilcox J, Augustine A, Goeddel DV, Lowe DG: Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol 1991; 11: 3454-3462.
40. Brown J, Zuo Z: Renal receptors for atria C-type natriuretic peptides in the rat. Am J Physiol 1992; 263: F89-F96.
41. Charles CJ, Espiner EA, Cameron VA, Richards AM, Yandle TG, Sybertz EJ: Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep. Hypertension 1991; 17: 643-651.
42. Stephenson SL, Kenny AJ: The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987; 243: 183-187.
43. Ura N, Carretero OA, Erdös EG: Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987; 32: 507-513.
44. Smits GJ, McGraw DE, Trapani AJ: Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects. Am J Physiol 1990; 258: F1417-F1424.
45. Dussaule JC, Stefanski A, Bea ML, Ronco P, Ardaillou R: Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 1983; 264: F45-F52.
46. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr: Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 1992; 263: H1318-H1321.
47. Kenny AJ, Bourne A, Ingram J: Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993; 291: 83-88.
48. Clavell AL, Stingo AJ, Wie CM, Heublein DM, Burnett JC Jr: C-type natriuretic peptide: a selective car-diovascular peptide. Am J Physiol 1993; 264: R290-R295.
49. Burnett JC Jr, Granger JP, Opgenorth TJ: Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984; 247: F863-F867.
50. Currie MG, Geller DM, Cole BR, et al: Purification and sequence analysis of bioactive atrial peptides (atriopeptins). Science 1984; 223: 67-69.
51. Brandt RR, Mattingly MT, Clavell AL, et al: Neutral endopeptidase inhibition results in a unique natriuresis in response to exogenous CNP. Am J Hypertens 1994; 7: 139A.
52. Seymour AA, Swerdel JN, Fennell SA, Druckman SP, Neubeck R, Delaney NG: Potentiation of the depressor responses to atrial natriuretic peptides in conscious SHR by an inhibitor of neutral endopeptidase. J Cardiovasc Pharmacol 1989; 14: 194-204.
53. Sybertz EJ Jr, Chiu PJS, Watkins RW, Vemulapalli S: Neutral metalloendopeptidase inhibition: a novel means of circulatory modulation. J Hypertens 1990; 8: S161-S167.
54. Sybertz EJ, Chiu PJS, Vemulapalli S; et al: SCH 39,370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate sodium hypertensive rats. J Pharmacol Exp Ther 1989; 250: 624-631.
55. Kambayashi Y, Nakao K, Kimura H, et al: Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun 1990; 173: 599-605.
56. Wilkins MR, Settle SL, Stockmann PT, Needleman P: Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci USA 1990; 87: 6465-6469.